Information Provided By: 
Fly News Breaks for June 27, 2017
REGN
Jun 27, 2017 | 07:53 EDT
Leerink analyst Geoffrey Porges raised his price target for Regeneron Pharmaceuticals to $573 to reflect higher expected sales of Dupixent, lower expected sales of Eylea due to some erosion by RTH258 starting in 2019, and including for the first time revenue from REGN2810. Regeneron shares are likely to benefit from "positive" Q2 results and further pipeline disclosures throughout the year, Porges tells investors in a research note. He reiterates an Outperform rating on the name.
News For REGN From the Last 2 Days
There are no results for your query REGN
